Serena Energia (SRNA3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Mar, 2026Executive summary
Net revenues rose 28% year-over-year in 4Q25 and 62% for the full year, driven by higher energy sales, but profitability declined due to increased energy purchase costs and curtailment impacts.
Adjusted EBITDA fell 36% year-over-year in 4Q25 and 13% for the year, reflecting lower energy production, reduced energy balance surpluses, and higher tax equity allocations.
Adjusted Net Income dropped 78% year-over-year in 4Q25 and turned negative for the full year, mainly due to lower EBIT and increased tax equity partner allocations.
Financial highlights
Adjusted Energy Gross Profit decreased 33% year-over-year in 4Q25 and 9% for the year.
Energy Gross Profit declined 16% year-over-year in 4Q25 but increased 3% for the year.
Adjusted EBITDA margin dropped 3 percentage points year-over-year in both 4Q25 and the full year.
Net Income fell 11% year-over-year in 4Q25 and 90% for the year.
Adjusted Net Debt stood at R$8.55 billion at year-end, with Net Debt/EBITDA LTM at 4.0x, up from 2.4x a year earlier.
Outlook and guidance
Energy production is expected to remain challenged by curtailment and variable wind conditions, with ongoing focus on operational efficiency and asset management.
Latest events from Serena Energia
- EBITDA up 22% YoY, guidance cut 5%, with asset growth and new contracts driving future margins.SRNA3
Q2 20242 Feb 2026 - EBITDA rose 26% in 2Q25, with 93% of output contracted and delisting process advancing.SRNA3
Q2 202523 Jan 2026 - EBITDA dropped 16% YoY from grid failures, but outlook brightens with US PPAs and take-private bid.SRNA3
Q1 202523 Jan 2026 - Take-private deal closed; revenue up, but net income and EBITDA declined on higher costs.SRNA3
Q3 202523 Jan 2026 - 3Q24 energy output up 19%, EBITDA up 12% Y/Y, guidance maintained, net income positive.SRNA3
Q3 202423 Jan 2026 - EBITDA rose 19% to BRL 1.95B, leverage improved, and 90% of output is pre-sold.SRNA3
Q4 202415 Dec 2025